ロード中...
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane....
保存先:
| 出版年: | Breast |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540343/ https://ncbi.nlm.nih.gov/pubmed/19914541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(09)70271-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|